Lesson plan

VR-1065

VR-1065 is a serotonin 5-HT 2C receptor agonist which was under development for the treatment of obesity but was never marketed. Its pharmacology has not been described. The drug was under development by Roche and Vernalis Group. It reached phase 1 clinical trials prior to the discontinuation of its development in 2002. The drug's development was discontinued due to suboptimal pharmacokinetics in phase 1 trials. The chemical structure of VR-1065 has not been disclosed.

Back to article

Article summary

VR-1065 is a serotonin 5-HT 2C receptor agonist which was under development for the treatment of obesity but was never marketed. Its pharmacology has not been described. The drug was under development by Roche and Vernalis Group. It reached phase 1 clinical trials prior to the discontinuation of its development in 2002. The drug's development was discontinued due to suboptimal pharmacokinetics in phase 1 trials. The chemical structure of VR-1065 has not been disclosed.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.